絞り込み

16732

広告

Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.

著者 Iwasaki J , Komori T , Nakagawa F , Nagase H , Uchida J , Matsuo K , Uto Y
Anticancer Res.2019 Jul ; 39(7):3553-3563.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Medical

Miscellaneous

Trabectedin is a DNA-damaging agent and has been approved for the treatment of patients with advanced soft tissue sarcoma. Schlafen 11 (SLFN11) was identified as a dominant determinant of the response to DNA-damaging agents. The aim of the study was to clarify the association between SLFN11 expression and the antitumor activity of trabectedin.
PMID: 31262879 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード